StockData
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. (ERNA) stock

ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.62−0.01 (-0.61%)

Close on Nov 18, 2026Market cap $2.64MP/E –Yield –

Ernexa Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Ernexa Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$7.05M. For fiscal 2025 it was -$7.05M. The highest annual figure on record is $2.62M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.05M–
FY2024Dec 31, 2024-$16.21M–
FY2023Dec 31, 2023-$20.43M–
FY2022Dec 31, 2022-$21.27M–
FY2021Dec 31, 2021-$23.64M–
FY2020Dec 31, 2020-$8.14M-411.2%
FY2019Dec 31, 2019$2.62M+264.9%
FY2018Dec 31, 2018$717.00K–
FY2017Dec 31, 2017-$179.00K–
FY2016Dec 31, 2016-$404.00K–
FY2015Dec 31, 2015-$5.17M–
FY2014Dec 31, 2014-$7.22M-1242.4%
FY2013Dec 31, 2013$632.00K-32.0%
FY2012Dec 31, 2012$930.00K–
FY2011Dec 31, 2011-$1.02M-167.6%
FY2010Dec 31, 2010$1.51M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.16M–
Q1 FY2026Mar 31, 2026-$2.27M–
Q4 FY2025Dec 31, 2025-$1.16M–
Q4 FY2024Dec 31, 2024-$3.55M–
Q3 FY2024Sep 30, 2024-$6.30M–
Q2 FY2024Jun 30, 2024-$2.51M–
Q1 FY2024Mar 31, 2024-$3.85M–
Q4 FY2023Dec 31, 2023-$4.68M–
Q3 FY2023Sep 30, 2023-$5.83M–
Q2 FY2023Jun 30, 2023-$3.87M–
Q1 FY2023Mar 31, 2023-$6.05M–
Q4 FY2022Dec 31, 2022-$5.46M–
Q3 FY2022Sep 30, 2022-$6.16M–
Q2 FY2022Jun 30, 2022-$4.18M–
Q1 FY2022Mar 31, 2022-$5.48M–
Q4 FY2021Dec 31, 2021-$6.98M–
Q3 FY2021Sep 30, 2021-$6.43M–
Q2 FY2021Jun 30, 2021-$6.80M–
Q1 FY2021Mar 31, 2021-$3.43M–
Q4 FY2020Dec 31, 2020-$1.65M-270.9%
Q3 FY2020Sep 30, 2020-$2.41M-717.1%
Q2 FY2020Jun 30, 2020-$2.21M-523.3%
Q1 FY2020Mar 31, 2020-$1.88M-354.1%
Q4 FY2019Dec 31, 2019$966.00K+101.3%
Q3 FY2019Sep 30, 2019$390.00K+40.3%
Q2 FY2019Jun 30, 2019$521.00K+110.1%
Q1 FY2019Mar 31, 2019$739.00K–
Q4 FY2018Dec 31, 2018$480.00K–
Q3 FY2018Sep 30, 2018$278.00K–
Q2 FY2018Jun 30, 2018$248.00K-91.8%
Q1 FY2018Mar 31, 2018-$289.00K–
Q4 FY2017Dec 31, 2017-$673.00K–
Q3 FY2017Sep 30, 2017-$1.97M–
Q2 FY2017Jun 30, 2017$3.03M–
Q1 FY2017Mar 31, 2017-$563.00K–
Q4 FY2016Dec 31, 2016-$70.00K–
Q3 FY2016Sep 30, 2016-$56.00K–

More Ernexa Therapeutics figures

See a number that looks wrong?